Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis: early-phase trial registry
120 of 317 indexed Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #24 of 28,707 conditions by registered trial count.
317 US clinical trials · 120 currently recruiting · #24 of 28,707 conditions by registered trial count
Multiple Sclerosis: 317 US clinical trials tracked, 120 recruiting.
Multiple Sclerosis is the subject of 317 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 41 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 13 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis
OPEN 120 | RECR 38% | LATE 41 | EARLY 74 | RANK #24 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Myeloma (38% recruiting · 441 trials)
Multiple Sclerosis lists 120 open slots (38% of 317 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis recruits in line with its size-band peers.
120 of 317 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 13 of 317 trials (4.1%). 142 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 316 trials that report a genuine target (sentinel values excluded). 181 of those (57.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis research is mostly interventional.
231 interventional and 86 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
317 total, page 5 of 7
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Beth Israel Deaconess Medical Center
NCT00179478
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
Cognition Pharmaceuticals
NCT00529581
Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
University at Buffalo
NCT02308670
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
Genentech
NCT03606460
CPAP to Treat Cognitive Dysfunction in MS
University of Michigan
NCT02544373
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
SpineX
NCT05301335
tDCS for the Management of Multiple Sclerosis Related Fatigue
NYU Langone Health
NCT03838770
Stress Management for Patients With Multiple Sclerosis
Northwestern University
NCT00147446
Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
US Department of Veterans Affairs
NCT00841321
Allocentric Memory in MS and Resting State Functional MRI
Yale University
NCT02118298
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
Elan Pharmaceuticals
NCT00047580
Natalizumab High Titer Immunogenicity and Safety
Biogen
NCT00516893
Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program
Shepherd Center, Atlanta GA
NCT03954717
Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers
Biogen
NCT01500408
Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study
University of Alabama at Birmingham
NCT03797378
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
Biogen
NCT02201849
Speed of Processing Training to Improve Cognition in Multiple Sclerosis
Kessler Foundation
NCT02301260
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
University of Colorado, Denver
NCT02588053
Whole Body Vibration Therapy in Participants With MS Related Balance Deficits
Logan College of Chiropractic
NCT00510523
Physical Telerehabilitation in Multiple Sclerosis
Columbia University
NCT03230903
The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients
National Institutes of Health Clinical Center (CC)
NCT00094068
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
University of Medicine and Dentistry of New Jersey
NCT00176592
FolateScan in Autoimmune Disease
Mayo Clinic
NCT00588393
Physical Telerehabilitation in Veterans With Multiple Sclerosis
University of Maryland
NCT02346734
Treatment of Sleep-disordered Breathing in Patients With SCI
VA Office of Research and Development
NCT02830074
GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
ConvaTec
NCT05470751
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Acorda Therapeutics
NCT01803867
Effects of Acthar on Recovery From Cognitive Relapses in MS
State University of New York at Buffalo
NCT02290444
Effects of Dalfampridine on Cognition in Multiple Sclerosis
State University of New York at Buffalo
NCT02006160
Cognitive Markers in Prodromal MS
NYU Langone Health
NCT05543915
MSPT Device Usability Study
Biogen
NCT02664324
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
University at Buffalo
NCT01695434
Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
Columbia University
NCT03824938
A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
UCB Pharma
NCT00139789
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
University of North Carolina, Chapel Hill
NCT00630721
A Teleheath tDCS Approach to Decrease Cannabis Use
NYU Langone Health
NCT05005013
Rolipram to Treat Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00011375
Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis
University of Missouri, Kansas City
NCT03889327
Promoting Physical Activity for Persons With Multiple Sclerosis
University of Minnesota
NCT00513448
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
University at Buffalo
NCT02021162
JC Virus Reactivation in Multiple Sclerosis
Beth Israel Deaconess Medical Center
NCT02004444
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Vaccinex
NCT01764737
MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis
National Institutes of Health Clinical Center (CC)
NCT00064909
Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis
Griffin Hospital
NCT03949296
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Dragonfly Research
NCT04837651
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Biogen
NCT01244139
Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis
University of Kansas Medical Center
NCT03783585
Digital Cognition in Multiple Sclerosis
University of California, San Francisco
NCT03569618
Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT
Kessler Foundation
NCT03677440
Gaze and Postural Stability in Multiple Sclerosis
University of Utah
NCT03521557
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 33 |
| Phase 3 | 24 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis page
317 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis condition card totals 317 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.